H5019
11-Hydroxy-Δ9-tetrahydrocannabinol
vacuum-dried powder
Synonim(y):
7-Hydroxy-Δ1-tetrahydrocannabinol
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
Informacje o tej pozycji
Wzór empiryczny (zapis Hilla):
C21H30O3
Numer CAS:
Masa cząsteczkowa:
330.46
UNSPSC Code:
41116107
MDL number:
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócform
vacuum-dried powder
drug control
USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
format
neat
storage temp.
−20°C
SMILES string
CCCCCc1cc(O)c2[C@@H]3C=C(CO)CC[C@H]3C(C)(C)Oc2c1
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Ta strona może zawierać tekst przetłumaczony maszynowo.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Klasa składowania
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Identification of 9 -tetrahydrocannabinol and metabolites in man.
M E Wall et al.
Journal of the American Chemical Society, 94(24), 8579-8581 (1972-11-29)
Cynthia Coulter et al.
Journal of analytical toxicology, 32(8), 653-658 (2008-11-15)
An analytical procedure for the determination of Delta9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCA), and 11-hydroxy-Delta9-tetrahydrocannabinol (11-OH-THC) in whole blood has been developed and validated using liquid chromatography with tandem mass spectral detection (MS). Cannabinoids present in the blood samples were quantified using
Erin L Karschner et al.
Clinical chemistry, 57(1), 66-75 (2010-11-17)
Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications